Overview

A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension

Status:
Terminated

Trial end date:
2011-07-01

Target enrollment:

Participant gender:

Summary

This is a multi-center, open-label study of sitaxsentan sodium 100 mg taken orally once daily by subjects with PAH until sitaxsentan, in a particular country or region, is commercially available for the treatment of PAH or the study is closed.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Sitaxsentan